Work for
the Enterprise

Learn more in Careers 

AIDS Vaccine 2009 - Paris, France 19-22 October

The Global HIV Vaccine Enterprise

is an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine by:

  • Shared scientific plan: Implementing a strategic plan for HIV vaccine research that spans vaccine discovery, product development and manufacturing, and clinical trials
  • Increased resources: Mobilizing significant new funding to achieve the scientific plan
  • Greater collaboration: Promoting more efficient, faster ways for researchers to share successes and failures and avoid duplication of efforts

The Enterprise Approach 



Latest News:

NIH Announces 2009 Director’s New Innovator Award Program – November 25, 2008

The National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services, is requesting applications for the 2009 NIH Director's New Innovator Award. The award supports creative new investigators who propose highly innovative projects that have the potential for unusually high impact on broad, important problems in biomedical and behavioral research. Pre-applications may be submitted to Grants.gov beginning December 15, 2008 and must be received no later than January 15, 2009. Please see the links below for more information.
2009 NIH Director’s New Innovator Award Website
Pre-Application for the 2009 NIH Director’s New Innovator Award Program

NIH Announces New Policy to Support Scientists Early in Their Careers – November 19, 2008

The National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services, announced a new policy to encourage funding for scientists new to NIH and those who are at an early stage in their careers. The goal of this policy is to nurture a new cadre of promising scientists and foster the next generation of biomedical research. Please see the link below for the full NIH press release.
New NIH Policy to Support Scientists Early in Their Careers

CHAVI and HVTN Issue Request for Applications for Early Career Investigator Scholar Award on Non-Human Primate Models – November 19, 2008

The Center for HIV/AIDS Vaccine Immunology (CHAVI), in collaboration with the HIV Vaccine Trials Network (HVTN), has issued a request for applications (RFA) for a new Early Career Investigator Scholar Award. The RFA invites early career investigators to submit proposals that strengthen bridges between non-human primate and human research as part of the effort to develop a safe and effective preventive HIV vaccine. Applications are due February 23, 2009. Please see the link below for the full RFA.
Early Career Investigator Scholar Award - Request for Applications

Enterprise Statement on New U.K. Support for HIV Prevention Technologies – November 14, 2008

Last week the U.K. Department for International Development (DFID) announced a £220 million fund to support research for the development of new HIV prevention technologies including a safe and effective preventive HIV vaccine. Please see the below link for a statement from Enterprise Executive Director Dr. Alan Bernstein commending the U.K. Government for its continued commitment to HIV prevention research.
Enterprise DFID Statement

Summary Statement on AIDS Vaccine 2008 and Enterprise Press Coverage – November 13, 2008

The Global HIV Vaccine Enterprise and the local hosts of AIDS Vaccine 2008 convened more than 900 of the world’s leading vaccine scientists, advocates, and policymakers in Cape Town, South Africa, from October 13-16, at the eighth annual AIDS Vaccine conference. Please see the link below for a statement on the conference from Enterprise Executive Director Dr. Alan Bernstein and Conference Chair Dr. Lynn Morris. In addition, please see the linked articles for conference press coverage.
Summary Statement      Cape Times Article      LA Times Article      Mail & Guardian Article 

More News from the Enterprise 

The Enterprise's scientific strategic plan for accelerating HIV vaccine research was published in the February 2005 issue of Public Library of Science (PLoS) — Medicine

All Content ©2005 - 2008 Global HIV Vaccine Enterprise